Skip to main content
Fig. 7 | Cancer Imaging

Fig. 7

From: Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

Fig. 7

Progressive disease on WBMRI not identified on CT. 80-year-old female with ER- PR- positive HER-2 negative infiltrating ductal carcinoma with bone metastases on first presentation. Tumour marker rise was noted whilst on Letrozole and Denusomab over a three-month period. WBMRI demonstrated clear progression at several sites but no changes were appreciated on CT performed at the same time points. In this figure high b-value (b900) image (A), corresponding ADC map (B) and derived fat fraction images from the Dixon sequences (C) demonstrate an increase in the size of the lesion at T11 with no appreciable change in the mixed lytic and sclerotic disease burden on CT (D)

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us